8-6OAS Immunomodulatory Effects of Adipose-Derived Stem Cell Secretome in a Mouse Model of Asthma  

Friday, 16 October 2015: 14:45 - 15:00
Room R2 ABC (Floor 3) (Coex Convention Center)

Kyu-Sup Cho , Pusan National University, Busan, South Korea

Hwan-Jung Roh , MD, PhD, South Korea

Background and Objectives: Several studies have demonstrated that adipose-derived stem cells (ASCs) can ameliorate allergic airway inflammation by shifting to a Th1 from a Th2-biased immune response. The ASCs secrete a variety of autocrine/paracrine factors, called secretome, that protect cells from apoptotic cell death and modulate immune system. In this study, we evaluated the effects of ASCs-derived secretome on allergic airway inflammation in ovalbumin (OVA) induced asthmatic mouse model.

Materials and Methods: C57BL/6 mice were sensitized to OVA by intraperitoneal injection and challenged intranasally with OVA. To evaluate the effect of ASCs-derived secretome on allergic airway disease, 1 μl/ml of ASCs supernatant were administrated intranasally before OVA challenge. We evaluated airway hyperresponsiveness (AHR), the proportion of eosinophils in bronchoalveolar lavage fluid (BALF), lung histology, serum total and OVA-specific antibody, cytokine profile of BALF and lung draining lymph nodes (LLN), and T cell population of LLN.

Results: ASCs-derived secretome significantly inhibited eosinophilic inflammation in the lung. AHR, total immune cell and eosinophils in the BALF, and mucus production were significantly reduced after ASCs-derived secretome administration. ASCs-derived secretome significantly decreased the serum total and allergen-specific IgE and IgG1 level. ASCs-derived secretome significantly inhibited Th2 cytokines (IL-4, IL-5, and IL-13) and enhanced Th1 cytokine (IFN-γ) and regulatory cytokines (IL-10 and TGF-β) in the BALF and LLN. In addition, CD25+Foxp3+ and IL-10+ T cells in LLN were significantly increased after ASCs-derived secretome administration.

Conclusions: ASCs-derived secretome ameliorated allergic airway inflammation and improved lung function through the induction of Tregs expansion. Secretome may be a promising candidate for a novel cell-free therapy for allergic airway diseases that has many advantages in overcoming the limitations and risks associated with the cell-based therapeutics.